A Novel Clinical Nomogram to Predict Transient Symptomatic Associated with Infarction: The ABCD3-SLOPE Score.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
03
2021
revised:
16
03
2021
accepted:
01
04
2021
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
22
6
2021
Statut:
epublish
Résumé
It is hard to differentiate transient symptoms associated with infarction (TSI) from transient ischemic stroke (TIA) without MRI in the early onset. However, they have distinct clinical outcomes and respond differently to therapeutics. Therefore, we aimed to develop a risk prediction model based on the clinical features to identify TSI. We enrolled 230 consecutive patients with transient neurologic deficit in the Department of Neurology, Tongji University Affiliated Tenth People's Hospital from March 2014 to October 2019. All the patients were assigned into TIA group (DWI-negative) or TSI group (DWI-positive) based on MRI conducted within five days of onset. We summarized the clinical characteristics of TSI by univariate and multivariate analyses. And then, we developed and validated a nomogram to identify TSI by the logistic regression equation. Of the 230 patients, 41.3% were diagnosed with TSI. According to the multivariate analysis, four independent risk factors, including smoking history, low-density lipoprotein cholesterol, brain natriuretic peptide precursor, and ABCD3 score, were incorporated into a nomogram. We developed a predictive model named ABCD3-SLOPE. The calibration curve showed good agreement between nomogram prediction and observation. The concordance index (C-index) of the nomogram for TSI prediction was 0.77 (95% confidence interval, 0.70-0.83), and it was well-calibrated. Smoking history, low-density lipoprotein cholesterol, brain natriuretic peptide precursor, and ABCD3 score were reliable risk factors for TSI. ABCD3-SLOPE was a potential tool to quantify the likelihood of TSI.
Sections du résumé
BACKGROUND
BACKGROUND
It is hard to differentiate transient symptoms associated with infarction (TSI) from transient ischemic stroke (TIA) without MRI in the early onset. However, they have distinct clinical outcomes and respond differently to therapeutics. Therefore, we aimed to develop a risk prediction model based on the clinical features to identify TSI.
METHODS
METHODS
We enrolled 230 consecutive patients with transient neurologic deficit in the Department of Neurology, Tongji University Affiliated Tenth People's Hospital from March 2014 to October 2019. All the patients were assigned into TIA group (DWI-negative) or TSI group (DWI-positive) based on MRI conducted within five days of onset. We summarized the clinical characteristics of TSI by univariate and multivariate analyses. And then, we developed and validated a nomogram to identify TSI by the logistic regression equation.
RESULTS
RESULTS
Of the 230 patients, 41.3% were diagnosed with TSI. According to the multivariate analysis, four independent risk factors, including smoking history, low-density lipoprotein cholesterol, brain natriuretic peptide precursor, and ABCD3 score, were incorporated into a nomogram. We developed a predictive model named ABCD3-SLOPE. The calibration curve showed good agreement between nomogram prediction and observation. The concordance index (C-index) of the nomogram for TSI prediction was 0.77 (95% confidence interval, 0.70-0.83), and it was well-calibrated.
CONCLUSIONS
CONCLUSIONS
Smoking history, low-density lipoprotein cholesterol, brain natriuretic peptide precursor, and ABCD3 score were reliable risk factors for TSI. ABCD3-SLOPE was a potential tool to quantify the likelihood of TSI.
Identifiants
pubmed: 33937400
doi: 10.1155/2021/5597155
pmc: PMC8062161
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5597155Informations de copyright
Copyright © 2021 YanQin Lu et al.
Déclaration de conflit d'intérêts
No conflict of interests by any of the authors.
Références
Int J Stroke. 2019 Feb;14(2):115-124
pubmed: 30507363
Stroke. 2014 Mar;45(3):765-9
pubmed: 24481972
QJM. 2009 Jan;102(1):43-9
pubmed: 18922827
BMC Neurol. 2016 Feb 09;16:20
pubmed: 26857238
Neuroradiology. 2013 Feb;55(2):157-63
pubmed: 22990364
Stroke. 2019 Aug;50(8):2080-2085
pubmed: 31693449
PLoS One. 2015 Sep 22;10(9):e0137425
pubmed: 26394400
Stroke. 2015 Aug;46(8):2325-7
pubmed: 26106113
Neurology. 2013 May 21;80(21):1920-6
pubmed: 23616156
Ann Neurol. 2014 Jan;75(1):67-76
pubmed: 24085376
Neurol Sci. 2020 Jul;41(7):1765-1771
pubmed: 32034558
Stroke. 2003 Apr;34(4):932-7
pubmed: 12637695
Neurology. 2017 Jan 17;88(3):237-244
pubmed: 27927939
Lancet. 2007 Oct 20;370(9596):1432-42
pubmed: 17928046
Platelets. 2020 Jul 3;31(5):667-673
pubmed: 31556777
Int J Dev Neurosci. 2011 Feb;29(1):63-9
pubmed: 20868735
J Stroke Cerebrovasc Dis. 2013 Oct;22(7):e25-30
pubmed: 22609319
Front Neurol. 2019 Jul 16;10:764
pubmed: 31379718
J Stroke Cerebrovasc Dis. 2015 Sep;24(9):2110-6
pubmed: 26142258
Stroke. 2014 Jul;45(7):2160-236
pubmed: 24788967
Am Heart J. 2015 Nov;170(5):914-22
pubmed: 26542499
Neurology. 2013 May 21;80(21):1914-5
pubmed: 23616166
Stroke. 2014 Feb;45(2):418-25
pubmed: 24335223
N Engl J Med. 2016 Apr 21;374(16):1533-42
pubmed: 27096581
Stroke. 2009 Jan;40(1):181-6
pubmed: 18948609
Ann Neurol. 2005 May;57(5):679-86
pubmed: 15852402
Stroke. 2009 Mar;40(3):749-53
pubmed: 19150868
JAMA Neurol. 2021 Jan 1;78(1):77-87
pubmed: 33044505
Eur J Neurol. 2013 Jul;20(7):1088-93
pubmed: 23530724
Lancet Neurol. 2009 Mar;8(3):235-43
pubmed: 19200786
Stroke. 2007 Aug;38(8):2367-9
pubmed: 17615367